Диссертация (1141201), страница 20
Текст из файла (страница 20)
– Vol.135. –P.297-30427.Ahad F. et al. Iodine, iodine metabolism and iodine deficiency disorders revisited//Indian journal of endocrinology and metabolism. – 2010. – Vol. 14. – №. 1. – P. 13.28.Alexander W. D. et al. Iodine and Thyroid Function: Physiological Significanceof the Plasma Inorganic Iodine 1 //The Journal of Clinical Endocrinology & Metabolism. – 1964.– Vol. 24. – №. 9.
– P. 851-856.29.Appelbaum PC. 2012 and beyond: potential for the start of a second pre-antibioticera?// J Antimicrob Chemother. – 2012. – Vol.67. - №9. – P. 2062-2068.30.Arai H, Nakajima H, Nagai R, Kaminaga Y, Mizoguchi S. A case ofMycobacterium chelonei infection of the skin.// Jpn J Clin Dermatol - 1983; - Vol.37. – P. 249–253.31.Bakavoli M. et al.
Molecular iodine promoted synthesis of new pyrazolo [3, 4-d]pyrimidine derivatives as potential antibacterial agents //European journal of medicinalchemistry. – 2010. – Vol. 45. – №. 2. – P. 647-650.32.Beale J. M., Block J., Hill R. A. Organic medicinal and pharmaceutical chemistry.– Philadelphia : Lippincott Williams & Wilkins, 2010.33.Bebko SP, Green DM, Awad SS. Effect of a preoperative decontaminationprotocol on surgical site infections in patients undergoing elective orthopedic surgery withhardware implantation.// JAMA Surg.
– 2015. – Vol. 150. №5. –P. 390-39534.Benevento W. J. et al. The sensitivity of Neisseria gonorrhoeae, Chlamydiatrachomatis, and herpes simplex type II to disinfection with povidone-iodine //American journalof ophthalmology. – 1990. – Vol. 109. – №. 3. – P. 329-333.35.Bennett JE. Agentesantifúngicos. In: Gilman AG, Goodman AG. //Goodman &Gilman: as bases farmacológicas da terapêutica. 10.ed. Rio de Janeiro: Guanabara-Koogan. 2001. P.
977-978.36.Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity ofdilute preparations of povidone-iodine solutions.// J Clin Microbiol. – 1982. – Vol.15. - №4. – P.635-63914337.Best M. et al. Efficacies of selected disinfectants against Mycobacteriumtuberculosis //Journal of Clinical Microbiology. – 1990. – Vol. 28.
– №. 10. – P. 2234-2239.38.Boudouma M, Enjalbert L, Didier J. A simple method for the evaluation ofantiseptic and disinfectant virucidal activity. // J Virol Methods. – 1984. –Vol. 9. - №4. – P. 27127639.Cap R., Hose F., Horyna P., Mala E., Horackova J., Plodr M., Sobotka L. Effectof Hyaluronateiodine-Complex in Skin Grafting of Chronic Infected Wounds, EWMA, May 14 –16, 2008, Lisbon, Portugal.40.Casewell MW, Hill RL. Elimination of nasal carriage of Staphylococcus aureuswith mupirocin ('pseudomonic acid')--a controlled trial.
// J Antimicrob Chemother. - 1986. –Vol. 17. - №3. - 365-37241.Childs Jr D. S. et al. The effect of varying quantities of inorganic iodide (carrier)on the urinary excretion and thyroidal accumulation of radioiodine in exophthalmic goiter//Journal of Clinical Investigation. – 1950. – Vol. 29. – №. 6. – P. 726.42.Chopra I. The 2012 Garrod lecture: discovery of antibacterial drugs in the 21stcentury. // J Antimicrob Chemother. – 2013.
– Vol. 68. - №3. – P. 496-50543.Chung H. R. Iodine and thyroid function //Annals of Pediatric Endocrinology &Metabolism. – 2014. – Vol. 19. – №. 1. – P. 8-1244.Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? //BrJ Pharmacol. – 2011. – Vol.
163. - №1. – P. 184-19445.Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrileneutrophilic dermatosis. // Orphanet J Rare Dis. – 2007. - Vol. 26. - №2. – P. 34.46.Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options.// Am J Clin Dermatol. – 2002. –Vol.3. - №2. – P. 117-13147.Cooper RA. Iodine revisited. // Int Wound J. – 2007. – Vol. 4. - №2. – P. 124-13748.Coskun B, Saral Y, Akpolat N, Ataseven A, Ciçek D.
Sporotrichosis successfullytreated with terbinafine and potassium iodide: case report and review of the literature. //Mycopathologia. – 2004. – Vol. 158. - №1. – P. 53-5649.Costa R. O. et al. Use of potassium iodide in dermatology: updates on an old drug//Anais brasileiros de dermatologia. – 2013. – Vol. 88. – №. 3. – P.
396-402.50.David E, Tramontin T, Zemmel R. Pharmaceutical R&D: the road topositivereturns. // Nat Rev Drug Discov. – 2009. - Vol.8. - №8. – P. 609-1014451.Daily Med US National Library of Medicine: [Электронный документ] / URL:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c951336f-9cb2-40cc-98f3b5c4d9f5e27d (Дата обращения: 11.03.16)52.De Wet PM, Rode H, Cywes S. Bactericidal efficacy of 5 per cent povidoneiodine cream in Pseudomonas aeruginosa burn wound infection.
// Burns. – 1990. – Vol. 16. №4. – P. 302-30653.De Vijlder J. J. M., Vulsma T. Hereditary metabolic disorders causinghypothyroidism //Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text. 8thed.(Braverman LE, Utiger RD, eds). Philadelphia: Lippincott Williams & Wilkins. – 2000. – P.733-742.54.DiMasi JA, Grabowski HG, Hansen RW.
Innovation in the pharmaceuticalindustry: New estimates of R&D costs. J // Health Econ. - 2016. - Vol. 12;47. - P. 20-3355.DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THECOUNCIL of 6 November 2001 on the Community code relating to medicinal products forhuman use: [Электронный документ] / URL: http://ec.europa.eu/health/files/eudralex/vol1/dir_2001_83_cons/dir2001_83_cons_20081230_en.pdf (Дата обращения 10.03.2016)56.Drugs@FDA:[Электронныйдокумент]/URL:https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (Дата обращения 04.03.2016)57.Dunn J.
T. et al. Methods for measuring iodine in urine. – 1993.58.Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins andevolution. // Nat Rev Drug Discov. - 2014. - Vol. 13(8). - P. 577-58759.Eeckhout E, Willemsen M, Deconinck A, Somers G. Granulomatous vasculitis asa complication of potassium iodide treatment for Sweet's syndrome. // Acta Derm Venereol.
1987. - Vol. 67. - P. 362-36460.Fan J. Pharmacokinetics / J. Fan, I.A. de Lannoy // Biochem Pharmacol. – 2014. –Vol. 87. – №1. – Р. 93-12061.Frankova J., Kubala L., Velebny V., Ciz M., Lojek A. The effect of hyaluoronancombined with KI3 complex (Hyodine wound dressing) on keratinocytes and immune cells..// J.Mater. Sci.:Mater. Med., 2006. - Vol. 17. - P.
891-898.62.Frieden E. (ed.). Biochemistry of the essential ultratrace elements. // SpringerScience & Business Media, 2012. – Vol. 3.63.Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW.The emergence of drug-resistant tuberculosis in New York City. // N Engl J Med. 1993. - Vol.14525. - P. 328. - №8.
- P. 521-526. Erratum in: N Engl J Med 1993. - Vol. 8. – P.329. - №2. - P.14864.Garnier JP. Rebuilding the R&D engine in big pharma. // Harv Bus Rev. 2008. -Vol. 86. - №5. - P. 68-70, 72-76, 12865.Gordon J. Clinical significance of methicillin-sensitive and methicillin-resistantStaphylococcus aureus in UK hospitals and the relevance of povidone-iodine in their control.Postgrad Med J. 1993. - Vol. 69. - №3. - P. 106-11666.Gupta M, Narang T, Kaur RJ, Manhas A, Saikia UN, Dogra S. A prospective caseseries evaluating efficacy and safety of combination of itraconazole and potassium iodide inrhinofacial conidiobolomycosis.
// Int J Dermatol. 2016 . - Vol. 55. - №2. - P. 208-21467.Harbison MA, Hammer SM. Inactivation of human immunodeficiency virus byBetadine products and chlorhexidine. // J Acquir Immune Defic Syndr. 1989. - Vol. 2. - №1. - P.16-2068.Hassan I, Keen A. Potassium iodide in dermatology. // Indian J DermatolVenereol Leprol 2012. - Vol. 78.
- P. 390–39369.Heilman RD. Drug development history, "overview," and what are GCPs? // QualAssur. 1995. - Vol. 4(1). - P. 75-7970.Hetzel B. S. et al. Iodine // Handbook of nutritionally essential mineral elements.– 1997. – P. 557-581.71.Heymann WR. Potassium iodide and the Wolff-Chaikoff effect: relevance for thedermatologist. // J Am Acad Dermatol. 2000. - Vol.
42. - P. 490-272.Hill RL, Casewell MW. The in-vitro activity of povidone-iodinecream againstStaphylococcus aureus and its bioavailability in nasal secretions. // J Hosp Infect. 2000. - Vol.45(3). - P. 198-20573.Hollander L, Fetterman GH . Fatal iododerma: the eleventh case reported in theliterature. // Arch Dermatol Syphilol. 1936. - Vol.
34. - P. 228-24174.Isenberg SJ, Apt L, Campeas D. Ocular applications of povidone-iodine. //Dermatology. 2002. - Vol. 204. - №1. - P. 92-95.75.Ishii K, Ishii N, Nakanaga K, Nakano K, Saito I, Asahina A. Mycobacteriumhaemophilum infection with prominent facial manifestation mimicking leprosy. // J Dermatol.2015. - Vol. 42. - №10.
- P. 992-99576.Ito H, Ito T, Hikida M, Yashiro J, Otsuka A, Kida H, Otsuki K. Outbreak ofhighly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodineproducts. // Dermatology. 2006. - Vol. 212. -№1. - P. 115-11814677.Jawetz E, Melnick JL, Adelberg EA. Review of Medical Microbiology, 16th edn.Los Altos: Medical Publications,198478.Jaya C, Job A, Mathai E, Antonisamy B. Evaluation of topical povidone-iodine inchronic suppurative otitis media. // Arch Otolaryngol Head Neck Surg.
2003. - Vol. 129(10). - P.1098-10079.Jellife DB, Wilson AM, Burkitt D. Subcutaneous phycomycosis responding tooral iodide therapy. // J Pediatr. 1962. - Vol. 6. - P. 448-45180.Joshi D. et al. Evaluation of antimicrobial efficacy of 0.5% IKI, 3% NaOCI and0.2% CHX when used alone and in combination as intracanal irrigants against EnterococcusFaecalis.–An in vitro study //Endodontology. – 2009. – Vol. 21.
– №. 2. – P. 6-16.81.Kanagalingam J, Feliciano R, Hah JH, Labib H, Le TA, Lin JC. Practical use ofpovidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatmentof common oropharyngeal infections. // Int J Clin Pract. 2015. - Vol. 69. -№11. - P. 1247-5682.Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious DiseasesSociety of America.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
